The $7.0 million asset sale is a small, contingent transaction tied to the merger's closing. Monitor stockholder vote and regulatory clearances for the merger, as the sale proceeds could modestly increase the per-share cash distribution.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $3.77entry
- T+1 · 20h ago −1.59%α +0.32% · $3.71
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics entered into an asset purchase agreement to sell its early-stage fetal hemoglobin (HbF) assets to an unaffiliated third party for approximately $7.0 million in cash. The sale is contingent on the closing of Fulcrum's proposed merger with Slate Medicines, and proceeds will be escrowed and credited to Fulcrum's net cash, potentially increasing the cash dividend expected in connection with the merger.
Key Facts
- On November 7, 2026, Fulcrum and Slate entered into an asset purchase agreement for the sale of early-stage HbF assets.
- The sale price is approximately $7.0 million in cash.
- Closing is contingent on consummation of the proposed merger (Merger Agreement dated August 16, 2026).
- Proceeds will be funded into escrow and credited to Fulcrum's net cash, potentially increasing the cash dividend from the merger.
Financial Impact
Approximately $7.0 million in cash proceeds, contingent on merger closing.
Risk Factors
- Asset sale closing is contingent on the merger closing; if the merger fails, the sale may require separate approvals.
- The $7.0 million amount is small relative to typical biotech deal sizes and may not materially affect the merger consideration.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-458387 |
| Document: 0001193125-26-458387-index-headers.html | 0001193125-26-458387 |
| Document: 0001193125-26-458387-index.html | 0001193125-26-458387 |
| Document: 0001193125-26-458387.txt | 0001193125-26-458387 |
Track record
23 reports on FULC
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Viewing Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers